EGFR and non-small cell lung carcinoma: Consequently, we provided a novel insight that blocking clathrin‐mediated EGFR endocytosis could be a therapeutic strategy for overcoming resistance to gefitinib in wild‐type EGFR NSCLC and new evidence of EGFR signaling mechanism via CME.